FDA Approves Unknown Drug — ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU

ALTOR BIOSCIENCE, LLC received FDA approval for its investigational therapy on April 22, marking a commercial milestone that could significantly bolster the company's valuation and shareholder value. This development validates the late-stage clinical program and places ALTOR on a more stable financial trajectory, reducing reliance on further external capital.